{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Gennex Laboratories Ltd
When is the next results date for Gennex Laboratories Ltd?
The next results date for Gennex Laboratories Ltd is 14 February 2026.
Gennex Laboratories Ltd is Rated Sell
Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Gennex Laboratories Ltd Downgraded to Sell Amid Technical Weakness and Financial Setbacks
Gennex Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, reflecting deteriorating technical indicators and disappointing financial performance. Despite a strong long-term growth record, recent quarterly results and bearish technical signals have prompted a reassessment of the stock’s outlook, signalling caution for investors amid underperformance relative to the broader market.
Gennex Laboratories Ltd Downgraded to Sell Amid Technical and Financial Weakness
Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 5 January 2026. This shift reflects a combination of deteriorating technical indicators, subdued financial performance, and valuation concerns, signalling caution for investors amid a challenging market environment.
Gennex Laboratories Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials
Gennex Laboratories Ltd has seen its investment rating upgraded from Sell to Hold as of 30 December 2025, driven primarily by a shift in technical indicators and a more attractive valuation profile. Despite recent financial setbacks, the company’s long-term growth prospects and improving market sentiment have contributed to this reassessment.
Gennex Laboratories Ltd is Rated Sell
Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with an up-to-date view of the company's performance and outlook.
Gennex Laboratories Faces Revised Market Assessment Amid Mixed Financial and Technical Signals
Gennex Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has experienced a shift in market evaluation following a detailed reassessment of its financial performance, valuation, technical indicators, and overall quality metrics. This article explores the factors influencing the recent changes in the company’s market standing and what investors should consider in light of these developments.
Gennex Lab. Sees Revision in Market Evaluation Amid Mixed Financial Signals
Gennex Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment follows a period marked by contrasting financial trends and valuation metrics, prompting a reassessment of the company’s standing within its sector and relative to market benchmarks.
Why is Gennex Lab. falling/rising?
On 21-Nov, Gennex Laboratories Ltd witnessed a notable decline in its share price, falling by 4.79% to close at ₹13.73. This drop reflects a continuation of recent downward momentum amid subdued investor interest and underperformance relative to broader market benchmarks.
Gennex Laboratories Faces Financial Challenges Amid Mixed Market Performance Trends
Gennex Laboratories has faced challenges in its financial performance for the quarter ending September 2025, with a decline in key metrics. Despite a record Profit After Tax, the company reported a drop in Profit Before Tax and a low Return on Capital Employed, alongside increased leverage and mixed market performance.
Why is Gennex Lab. falling/rising?
As of 17-Nov, Gennex Laboratories Ltd's stock price is 15.05, down 4.51%, and has significantly underperformed its sector and the Sensex over the past year. The decline in investor participation and inability to maintain momentum suggest a lack of confidence in the company's prospects.
How has been the historical performance of Gennex Lab.?
Gennex Lab has demonstrated significant growth in net sales and profitability, with net sales increasing from 55.62 Cr in Mar'20 to 137.90 Cr in Mar'25, and profit after tax rising from 1.86 Cr to 18.12 Cr in the same period, despite rising raw material costs and negative cash flow in recent years. Total assets grew from 56.94 Cr to 255.86 Cr, indicating strong overall financial expansion.
How has been the historical performance of Gennex Lab.?
Gennex Lab has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales increasing from 69.55 Cr to 137.90 Cr and profit after tax rising from 4.92 Cr to 18.12 Cr, despite rising raw material costs and negative cash flow in 2025. Total assets and liabilities both grew to 255.86 Cr during this period.
Why is Gennex Lab. falling/rising?
As of 12-Nov, Gennex Laboratories Ltd is currently experiencing a price increase to 15.96, with a notable rise of 1.66% recently. Despite strong short-term performance, the stock has seen a year-to-date decline of 2.33% and a significant drop in delivery volume, which may affect future trading activity.
Gennex Laboratories Forms Golden Cross, Signaling Potential Bullish Breakout
Gennex Laboratories has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock has shown strong short-term performance, with notable gains over the past week and month. Despite a challenging one-year performance, technical indicators suggest a bullish sentiment, attracting investor interest amid its recovery phase.
Why is Gennex Lab. falling/rising?
As of 10-Nov, Gennex Laboratories Ltd is currently priced at 15.11, reflecting a 5.96% increase after a trend reversal. Despite a drop in investor participation, the stock has outperformed its sector today and has risen 23.95% over the past month, although it remains down year-to-date and over the past year.
Is Gennex Lab. overvalued or undervalued?
As of November 7, 2025, Gennex Lab's valuation is considered attractive with a PE ratio of 19.66, favorable compared to peers like Sun Pharma and Divi's Lab, and despite recent underperformance, it has shown strong long-term growth of 296.11% over five years.
Is Gennex Lab. overvalued or undervalued?
As of November 7, 2025, Gennex Lab. is considered fairly valued with a PE ratio of 19.66, lower than its peers Sun Pharma and Divi's Lab., and while it has underperformed the Sensex in the past year with a -32.10% return, it has achieved a substantial 296.11% return over the last five years.
Is Gennex Lab. overvalued or undervalued?
As of November 7, 2025, Gennex Lab. is considered overvalued with a PE ratio of 19.66 and an attractive valuation grade, despite lower PE ratios than some peers like Sun Pharma and Divi's Lab., but higher than Cipla and Dr. Reddy's Labs, and has underperformed with a year-to-date return of -12.73% compared to the Sensex's 6.50%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
